$GNMK Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in GenMark Diagnostics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in GenMark Diagnostics, Inc.. Get notifications about new insider transactions in GenMark Diagnostics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Giles Lisa M. | Director | Option Exercise | D | 13.17 | 19,062 | 251,047 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Giles Lisa M. | Director | Sell | U | 24.05 | 5,500 | 132,275 | 0 | 5.5 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Giles Lisa M. | Director | Sell | U | 24.05 | 81,572 | 1,961,807 | 0 | 81.6 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Kagnoff Michael | Director | Option Exercise | D | 13.17 | 19,062 | 251,047 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Kagnoff Michael | Director | Sell | U | 24.05 | 137,319 | 3,302,522 | 0 | 137.3 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Fox James | Director | Sell | U | 24.05 | 81,085 | 1,950,094 | 0 | 81.1 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Fox James | Director | Sell | U | 24.05 | 182,017 | 4,377,509 | 0 | 182 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | FAULKNER DARYL | Director | Option Exercise | D | 4.38 | 10,741 | 47,046 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | FAULKNER DARYL | Director | Sell | U | 24.05 | 133,871 | 3,219,598 | 0 | 133.9 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | OBOYLE KEVIN C | Director | Option Exercise | D | 4.38 | 13,426 | 58,806 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | OBOYLE KEVIN C | Director | Sell | U | 24.05 | 131,678 | 3,166,856 | 0 | 131.7 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Stevenson Wade R. | SVP, North America ... | Sell | U | 24.05 | 50,000 | 1,202,500 | 0 | 50 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Shaw Christine | VP, Assay Developme ... | Option Exercise | D | 0.00 | 17,500 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Shaw Christine | VP, Assay Developme ... | Sell | U | 24.05 | 101,324 | 2,436,842 | 0 | 101.3 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Winkler Sarah Hollis | VP, Human Resources | Option Exercise | D | 0.00 | 12,500 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Winkler Sarah Hollis | VP, Human Resources | Option Exercise | D | 0.00 | 33,334 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Winkler Sarah Hollis | VP, Human Resources | Option Exercise | D | 0.00 | 6,668 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Winkler Sarah Hollis | VP, Human Resources | Sell | U | 24.05 | 147,502 | 3,547,423 | 0 | 147.5 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Maderazo Alan Baer | VP, Qual, Reg, & Cl ... | Option Exercise | D | 0.00 | 15,000 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Maderazo Alan Baer | VP, Qual, Reg, & Cl ... | Option Exercise | D | 0.00 | 33,334 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Maderazo Alan Baer | VP, Qual, Reg, & Cl ... | Option Exercise | D | 0.00 | 13,332 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Maderazo Alan Baer | VP, Qual, Reg, & Cl ... | Sell | U | 24.05 | 262,180 | 6,305,429 | 0 | 262.2 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Jensen Tyler | SVP, Engineering an ... | Option Exercise | D | 0.00 | 12,500 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Jensen Tyler | SVP, Engineering an ... | Option Exercise | D | 0.00 | 40,000 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Jensen Tyler | SVP, Engineering an ... | Option Exercise | D | 0.00 | 11,668 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Jensen Tyler | SVP, Engineering an ... | Sell | U | 24.05 | 212,249 | 5,104,588 | 0 | 212.2 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | O'Brien Scott Alexander | SVP, Global Mktg & ... | Option Exercise | D | 10.89 | 1,500 | 16,335 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | O'Brien Scott Alexander | SVP, Global Mktg & ... | Option Exercise | D | 12.30 | 5,200 | 63,960 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | O'Brien Scott Alexander | SVP, Global Mktg & ... | Option Exercise | D | 13.17 | 8,500 | 111,945 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | O'Brien Scott Alexander | SVP, Global Mktg & ... | Option Exercise | D | 7.90 | 10,000 | 79,000 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | O'Brien Scott Alexander | SVP, Global Mktg & ... | Option Exercise | D | 0.00 | 25,000 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | O'Brien Scott Alexander | SVP, Global Mktg & ... | Option Exercise | D | 0.00 | 33,334 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | O'Brien Scott Alexander | SVP, Global Mktg & ... | Sell | U | 24.05 | 170,879 | 4,109,640 | 0 | 170.9 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Chohan Abdul | SVP Operations | Option Exercise | D | 0.00 | 12,500 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Chohan Abdul | SVP Operations | Sell | U | 24.05 | 63,750 | 1,533,188 | 0 | 63.8 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Stier Eric | SVP & General Couns ... | Option Exercise | D | 13.17 | 55,550 | 731,594 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Stier Eric | SVP & General Couns ... | Option Exercise | D | 12.30 | 62,000 | 762,600 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Stier Eric | SVP & General Couns ... | Option Exercise | D | 8.50 | 30,000 | 255,000 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Stier Eric | SVP & General Couns ... | Option Exercise | D | 0.00 | 12,500 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Stier Eric | SVP & General Couns ... | Option Exercise | D | 0.00 | 35,000 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Stier Eric | SVP & General Couns ... | Option Exercise | D | 0.00 | 15,832 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Stier Eric | SVP & General Couns ... | Sell | U | 24.05 | 275,974 | 6,637,175 | 0 | 276 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Harkins Michael John | SVP, Sales | Option Exercise | D | 0.00 | 7,500 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Harkins Michael John | SVP, Sales | Option Exercise | D | 0.00 | 38,334 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Harkins Michael John | SVP, Sales | Sell | U | 24.05 | 144,214 | 3,468,347 | 0 | 144.2 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Option Exercise | D | 0.00 | 12,500 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Option Exercise | D | 0.00 | 38,334 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Option Exercise | D | 0.00 | 16,668 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Option Exercise | D | 13.17 | 55,674 | 733,227 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Option Exercise | D | 12.30 | 62,046 | 763,166 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Option Exercise | D | 10.89 | 20,213 | 220,120 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Sell | U | 24.05 | 30,069 | 723,159 | 0 | 30.1 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Sell | U | 24.05 | 421,383 | 10,134,261 | 0 | 421.4 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Ek John Frederick | Chief Financial Off ... | Option Exercise | D | 13.17 | 17,000 | 223,890 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Ek John Frederick | Chief Financial Off ... | Option Exercise | D | 11.59 | 17,000 | 197,030 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Ek John Frederick | Chief Financial Off ... | Option Exercise | D | 0.00 | 30,000 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Ek John Frederick | Chief Financial Off ... | Option Exercise | D | 0.00 | 46,666 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Ek John Frederick | Chief Financial Off ... | Option Exercise | D | 0.00 | 16,668 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Ek John Frederick | Chief Financial Off ... | Sell | U | 24.05 | 232,993 | 5,603,482 | 0 | 233 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Mendel Scott | President & CEO | Option Exercise | D | 13.17 | 35,552 | 468,220 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Mendel Scott | President & CEO | Option Exercise | D | 9.43 | 84,002 | 792,139 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Mendel Scott | President & CEO | Option Exercise | D | 0.00 | 53,382 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Mendel Scott | President & CEO | Option Exercise | D | 0.00 | 100,000 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Mendel Scott | President & CEO | Option Exercise | D | 0.00 | 28,332 | 0 | 0 | |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Mendel Scott | President & CEO | Sell | U | 24.05 | 115,491 | 2,777,559 | 0 | 115.5 K to 0 (-100.00 %) |
| Apr 22 2021 | GNMK | GenMark Diagnostic ... | Mendel Scott | President & CEO | Sell | U | 24.05 | 507,198 | 12,198,112 | 0 | 507.2 K to 0 (-100.00 %) |
| Apr 16 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Option Exercise | M | 10.89 | 12,787 | 139,250 | 12,001 | |
| Apr 16 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Option Exercise | M | 13.17 | 4,926 | 64,875 | 989 | |
| Apr 16 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Option Exercise | M | 12.30 | 9,954 | 122,434 | 5,118 | |
| Apr 16 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Buy | M | 10.89 | 12,787 | 139,250 | 420,410 | 407.6 K to 420.4 K (+3.14 %) |
| Apr 16 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Buy | M | 13.17 | 4,926 | 64,875 | 407,623 | 402.7 K to 407.6 K (+1.22 %) |
| Apr 16 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Buy | M | 12.30 | 9,954 | 122,434 | 402,697 | 392.7 K to 402.7 K (+2.53 %) |
| Apr 12 2021 | GNMK | GenMark Diagnostic ... | Stevenson Wade R. | SVP, North America ... | Grant | A | 0.00 | 50,000 | 0 | 50,000 | 0 to 50 K |
| Apr 06 2021 | GNMK | GenMark Diagnostic ... | Shaw Christine | VP, Assay Developme ... | Payment of Exercise | F | 0.00 | 1,730 | 0 | 100,466 | 102.2 K to 100.5 K (-1.69 %) |
| Mar 22 2021 | GNMK | GenMark Diagnostic ... | Jensen Tyler | SVP, Engineering an ... | Sell | S | 23.88 | 500 | 11,940 | 211,888 | 212.4 K to 211.9 K (-0.24 %) |
| Mar 08 2021 | GNMK | GenMark Diagnostic ... | O'Brien Scott Alexander | SVP, Global Mktg & ... | Payment of Exercise | F | 0.00 | 735 | 0 | 170,879 | 171.6 K to 170.9 K (-0.43 %) |
| Mar 08 2021 | GNMK | GenMark Diagnostic ... | Jensen Tyler | SVP, Engineering an ... | Sell | S | 18.86 | 500 | 9,430 | 212,388 | 212.9 K to 212.4 K (-0.23 %) |
| Mar 08 2021 | GNMK | GenMark Diagnostic ... | Shaw Christine | VP, Assay Developme ... | Sell | S | 18.56 | 274 | 5,085 | 102,196 | 102.5 K to 102.2 K (-0.27 %) |
| Mar 01 2021 | GNMK | GenMark Diagnostic ... | Stier Eric | SVP & General Couns ... | Payment of Exercise | F | 0.00 | 14,642 | 0 | 275,974 | 290.6 K to 276 K (-5.04 %) |
| Mar 01 2021 | GNMK | GenMark Diagnostic ... | Mendel Scott | President & CEO | Payment of Exercise | F | 0.00 | 41,834 | 0 | 507,198 | 549 K to 507.2 K (-7.62 %) |
| Mar 01 2021 | GNMK | GenMark Diagnostic ... | Ek John Frederick | Chief Financial Off ... | Payment of Exercise | F | 0.00 | 19,248 | 0 | 232,993 | 252.2 K to 233 K (-7.63 %) |
| Mar 01 2021 | GNMK | GenMark Diagnostic ... | O'Brien Scott Alexander | SVP, Global Mktg & ... | Payment of Exercise | F | 0.00 | 9,726 | 0 | 171,614 | 181.3 K to 171.6 K (-5.36 %) |
| Mar 01 2021 | GNMK | GenMark Diagnostic ... | Jensen Tyler | SVP, Engineering an ... | Payment of Exercise | F | 0.00 | 16,734 | 0 | 212,888 | 229.6 K to 212.9 K (-7.29 %) |
| Mar 01 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Sell | S | 17.01 | 17,750 | 301,928 | 392,743 | 410.5 K to 392.7 K (-4.32 %) |
| Mar 01 2021 | GNMK | GenMark Diagnostic ... | Harkins Michael John | SVP, Sales | Sell | S | 17.03 | 12,381 | 210,848 | 143,611 | 156 K to 143.6 K (-7.94 %) |
| Mar 01 2021 | GNMK | GenMark Diagnostic ... | Winkler Sarah Hollis | VP, Human Resources | Sell | S | 17.01 | 11,181 | 190,189 | 147,502 | 158.7 K to 147.5 K (-7.05 %) |
| Mar 01 2021 | GNMK | GenMark Diagnostic ... | Shaw Christine | VP, Assay Developme ... | Sell | S | 17.03 | 3,151 | 53,662 | 102,470 | 105.6 K to 102.5 K (-2.98 %) |
| Feb 25 2021 | GNMK | GenMark Diagnostic ... | Stier Eric | SVP & General Couns ... | Payment of Exercise | F | 0.00 | 2,208 | 0 | 290,616 | 292.8 K to 290.6 K (-0.75 %) |
| Feb 25 2021 | GNMK | GenMark Diagnostic ... | Maderazo Alan Baer | VP, Qual, Reg, & Cl ... | Sell | S | 19.16 | 266 | 5,097 | 278,253 | 278.5 K to 278.3 K (-0.10 %) |
| Feb 25 2021 | GNMK | GenMark Diagnostic ... | Maderazo Alan Baer | VP, Qual, Reg, & Cl ... | Payment of Exercise | F | 0.00 | 1,744 | 0 | 278,519 | 280.3 K to 278.5 K (-0.62 %) |
| Feb 25 2021 | GNMK | GenMark Diagnostic ... | Mendel Scott | President & CEO | Payment of Exercise | F | 0.00 | 3,254 | 0 | 549,032 | 552.3 K to 549 K (-0.59 %) |
| Feb 25 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Sell | S | 19.12 | 2,463 | 47,093 | 410,493 | 413 K to 410.5 K (-0.60 %) |
| Feb 25 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Sell | S | 19.35 | 1,432 | 27,709 | 412,956 | 414.4 K to 413 K (-0.35 %) |
| Feb 25 2021 | GNMK | GenMark Diagnostic ... | Shaw Christine | VP, Assay Developme ... | Sell | S | 19.12 | 259 | 4,952 | 105,621 | 105.9 K to 105.6 K (-0.24 %) |
| Feb 25 2021 | GNMK | GenMark Diagnostic ... | Shaw Christine | VP, Assay Developme ... | Sell | S | 19.35 | 166 | 3,212 | 105,880 | 106 K to 105.9 K (-0.16 %) |
| Feb 25 2021 | GNMK | GenMark Diagnostic ... | Jensen Tyler | SVP, Engineering an ... | Payment of Exercise | F | 0.00 | 1,163 | 0 | 229,622 | 230.8 K to 229.6 K (-0.50 %) |
| Feb 25 2021 | GNMK | GenMark Diagnostic ... | O'Brien Scott Alexander | SVP, Global Mktg & ... | Payment of Exercise | F | 0.00 | 735 | 0 | 181,340 | 182.1 K to 181.3 K (-0.40 %) |
| Feb 25 2021 | GNMK | GenMark Diagnostic ... | Ek John Frederick | Chief Financial Off ... | Payment of Exercise | F | 0.00 | 908 | 0 | 252,241 | 253.1 K to 252.2 K (-0.36 %) |
| Feb 24 2021 | GNMK | GenMark Diagnostic ... | Jensen Tyler | SVP, Engineering an ... | Payment of Exercise | F | 0.00 | 434 | 0 | 230,785 | 231.2 K to 230.8 K (-0.19 %) |
| Feb 24 2021 | GNMK | GenMark Diagnostic ... | O'Brien Scott Alexander | SVP, Global Mktg & ... | Payment of Exercise | F | 0.00 | 390 | 0 | 182,075 | 182.5 K to 182.1 K (-0.21 %) |
| Feb 24 2021 | GNMK | GenMark Diagnostic ... | Ek John Frederick | Chief Financial Off ... | Payment of Exercise | F | 0.00 | 487 | 0 | 253,149 | 253.6 K to 253.1 K (-0.19 %) |
| Feb 24 2021 | GNMK | GenMark Diagnostic ... | Stier Eric | SVP & General Couns ... | Payment of Exercise | F | 0.00 | 1,337 | 0 | 292,824 | 294.2 K to 292.8 K (-0.45 %) |
| Feb 24 2021 | GNMK | GenMark Diagnostic ... | Mendel Scott | President & CEO | Payment of Exercise | F | 0.00 | 1,860 | 0 | 552,286 | 554.1 K to 552.3 K (-0.34 %) |
| Feb 24 2021 | GNMK | GenMark Diagnostic ... | Maderazo Alan Baer | VP, Qual, Reg, & Cl ... | Sell | S | 19.12 | 163 | 3,117 | 280,263 | 280.4 K to 280.3 K (-0.06 %) |
| Feb 24 2021 | GNMK | GenMark Diagnostic ... | Maderazo Alan Baer | VP, Qual, Reg, & Cl ... | Payment of Exercise | F | 0.00 | 1,070 | 0 | 280,426 | 281.5 K to 280.4 K (-0.38 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | O'Brien Scott Alexander | SVP, Global Mktg & ... | Option Exercise | A | 0.00 | 12,500 | 0 | 12,500 | |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | O'Brien Scott Alexander | SVP, Global Mktg & ... | Grant | A | 0.00 | 37,500 | 0 | 182,465 | 145 K to 182.5 K (+25.87 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Winkler Sarah Hollis | VP, Human Resources | Option Exercise | A | 0.00 | 6,250 | 0 | 6,250 | |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Winkler Sarah Hollis | VP, Human Resources | Sell | S | 21.80 | 654 | 14,257 | 158,683 | 159.3 K to 158.7 K (-0.41 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Winkler Sarah Hollis | VP, Human Resources | Grant | A | 0.00 | 18,750 | 0 | 159,337 | 140.6 K to 159.3 K (+13.34 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Stier Eric | SVP & General Couns ... | Option Exercise | A | 0.00 | 6,250 | 0 | 6,250 | |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Stier Eric | SVP & General Couns ... | Grant | A | 0.00 | 18,750 | 0 | 294,161 | 275.4 K to 294.2 K (+6.81 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Stier Eric | SVP & General Couns ... | Payment of Exercise | F | 0.00 | 2,208 | 0 | 275,411 | 277.6 K to 275.4 K (-0.80 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Option Exercise | A | 0.00 | 6,250 | 0 | 6,250 | |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Sell | S | 21.80 | 2,340 | 51,012 | 414,388 | 416.7 K to 414.4 K (-0.56 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Grant | A | 0.00 | 18,750 | 0 | 416,728 | 398 K to 416.7 K (+4.71 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Shaw Christine | VP, Assay Developme ... | Option Exercise | A | 0.00 | 8,750 | 0 | 8,750 | |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Shaw Christine | VP, Assay Developme ... | Grant | A | 0.00 | 26,250 | 0 | 106,046 | 79.8 K to 106 K (+32.90 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Ek John Frederick | Chief Financial Off ... | Option Exercise | A | 0.00 | 15,000 | 0 | 15,000 | |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Ek John Frederick | Chief Financial Off ... | Grant | A | 0.00 | 45,000 | 0 | 253,636 | 208.6 K to 253.6 K (+21.57 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Ek John Frederick | Chief Financial Off ... | Payment of Exercise | F | 0.00 | 1,622 | 0 | 208,636 | 210.3 K to 208.6 K (-0.77 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Maderazo Alan Baer | VP, Qual, Reg, & Cl ... | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Maderazo Alan Baer | VP, Qual, Reg, & Cl ... | Sell | S | 20.36 | 290 | 5,904 | 281,496 | 281.8 K to 281.5 K (-0.10 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Maderazo Alan Baer | VP, Qual, Reg, & Cl ... | Grant | A | 0.00 | 22,500 | 0 | 281,786 | 259.3 K to 281.8 K (+8.68 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Maderazo Alan Baer | VP, Qual, Reg, & Cl ... | Payment of Exercise | F | 0.00 | 1,820 | 0 | 259,286 | 261.1 K to 259.3 K (-0.70 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Harkins Michael John | SVP, Sales | Option Exercise | A | 0.00 | 3,750 | 0 | 3,750 | |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Harkins Michael John | SVP, Sales | Grant | A | 0.00 | 11,250 | 0 | 155,992 | 144.7 K to 156 K (+7.77 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Chohan Abdul | SVP Operations | Option Exercise | A | 0.00 | 6,250 | 0 | 6,250 | |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Chohan Abdul | SVP Operations | Grant | A | 0.00 | 18,750 | 0 | 63,750 | 45 K to 63.8 K (+41.67 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Mendel Scott | President & CEO | Option Exercise | A | 0.00 | 26,691 | 0 | 26,691 | |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Mendel Scott | President & CEO | Grant | A | 0.00 | 80,070 | 0 | 554,146 | 474.1 K to 554.1 K (+16.89 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Mendel Scott | President & CEO | Payment of Exercise | F | 0.00 | 3,952 | 0 | 474,076 | 478 K to 474.1 K (-0.83 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Jensen Tyler | SVP, Engineering an ... | Option Exercise | A | 0.00 | 6,250 | 0 | 6,250 | |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Jensen Tyler | SVP, Engineering an ... | Grant | A | 0.00 | 18,750 | 0 | 231,219 | 212.5 K to 231.2 K (+8.82 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Jensen Tyler | SVP, Engineering an ... | Payment of Exercise | F | 0.00 | 1,628 | 0 | 212,469 | 214.1 K to 212.5 K (-0.76 %) |
| Feb 22 2021 | GNMK | GenMark Diagnostic ... | Jensen Tyler | SVP, Engineering an ... | Sell | S | 21.68 | 500 | 10,840 | 214,097 | 214.6 K to 214.1 K (-0.23 %) |
| Feb 19 2021 | GNMK | GenMark Diagnostic ... | Kagnoff Michael | Director | Grant | A | 0.00 | 6,880 | 0 | 137,319 | 130.4 K to 137.3 K (+5.27 %) |
| Feb 19 2021 | GNMK | GenMark Diagnostic ... | FAULKNER DARYL | Director | Grant | A | 0.00 | 7,402 | 0 | 133,871 | 126.5 K to 133.9 K (+5.85 %) |
| Feb 19 2021 | GNMK | GenMark Diagnostic ... | Fox James | Director | Grant | A | 0.00 | 7,355 | 0 | 182,017 | 174.7 K to 182 K (+4.21 %) |
| Feb 19 2021 | GNMK | GenMark Diagnostic ... | OBOYLE KEVIN C | Director | Grant | A | 0.00 | 10,130 | 0 | 131,678 | 121.5 K to 131.7 K (+8.33 %) |
| Feb 19 2021 | GNMK | GenMark Diagnostic ... | Giles Lisa M. | Director | Grant | A | 0.00 | 7,782 | 0 | 81,572 | 73.8 K to 81.6 K (+10.55 %) |
| Feb 08 2021 | GNMK | GenMark Diagnostic ... | Jensen Tyler | SVP, Engineering an ... | Sell | S | 14.69 | 500 | 7,345 | 224,597 | 225.1 K to 224.6 K (-0.22 %) |
| Jan 29 2021 | GNMK | GenMark Diagnostic ... | Maderazo Alan Baer | VP, Qual, Reg, & Cl ... | Sell | S | 15.19 | 6,214 | 94,391 | 261,106 | 267.3 K to 261.1 K (-2.32 %) |
| Jan 29 2021 | GNMK | GenMark Diagnostic ... | Jensen Tyler | SVP, Engineering an ... | Sell | S | 14.06 | 322 | 4,527 | 225,097 | 225.4 K to 225.1 K (-0.14 %) |
| Jan 29 2021 | GNMK | GenMark Diagnostic ... | O'Brien Scott Alexander | SVP, Global Mktg & ... | Sell | S | 14.06 | 180 | 2,531 | 144,965 | 145.1 K to 145 K (-0.12 %) |
| Jan 25 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Option Exercise | M | 0.00 | 19,166 | 0 | 19,167 | |
| Jan 25 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Option Exercise | M | 0.00 | 27,115 | 0 | 8,333 | |
| Jan 25 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Option Exercise | M | 0.00 | 37,555 | 0 | 0 | |
| Jan 25 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Sell | S | 14.22 | 33,027 | 469,644 | 397,978 | 431 K to 398 K (-7.66 %) |
| Jan 25 2021 | GNMK | GenMark Diagnostic ... | Gleeson Michael | SVP, Corp. Accounts | Buy | M | 0.00 | 19,166 | 0 | 431,005 | 411.8 K to 431 K (+4.65 %) |